Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alexion Pumps Up Its Rare Disease Portfolio With Enobia Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Alexion could pay as much as $1.08 billion for access to Enobia's mid-stage rare disease compound asfotase alpha.

You may also be interested in...

No One-Trick Pony: Alexion’s Evolution Into A Multi-Asset Drug Company

Alexion has been recognized mainly as the marketer of Soliris since 2007, but in just eight weeks the rare disease specialist added two new drugs to its commercial portfolio. Management also laid out an impressive early- to mid-stage pipeline during its first-ever investor day, suggesting the company is well positioned for long-term growth.

Alexion’s Bell Notes The Changing Role Of Innovation In Regulatory Decisions

CEO of the ultra-rare disease focused biotech spoke about the challenges of launching a drug for a relatively unknown disease and how innovation is playing an increasing role in R&D.

Breakthrough Math: Alexion Gains $400 Million on Asfotase Breakthrough Designation

There’s a lively debate underway as to what FDA’s new breakthrough designation means for a sponsor and for the likelihood of a product’s regulatory and commercial success. Alexion’s post-Memorial Day bump dramatizes the positive impact on Wall Street.

Related Content


Related Companies

Related Deals

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts